Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
0(0%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_1
3
75%
Ph early_phase_1
1
25%

Phase Distribution

4

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution4 total trials
Early Phase 1First-in-human
1(25.0%)
Phase 1Safety & dosage
3(75.0%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

100.0%

2 of 2 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

4

all time

Status Distribution
Active(1)
Completed(2)
Other(1)

Detailed Status

Completed2
Not yet recruiting1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
0
Success Rate
100.0%
Most Advanced
Early Phase 1

Trials by Phase

Early Phase 11 (25.0%)
Phase 13 (75.0%)

Trials by Status

not_yet_recruiting125%
unknown125%
completed250%

Recent Activity

0 active trials
Showing 4 of 4
completedphase_1

CD19 CAR T Cells in Patients With Relapsed or Refractory CD19 Positive B-cell Lymphoma

NCT03029338
not_yet_recruitingearly_phase_1

Autologous Bedside CD19 CAR T-cell Therapy for B-ALL

NCT07277504
completedphase_1

CD19 CAR T Cells in Patients With Resistant or Refractory CD19+ Acute Lymphoblastic Leukemia

NCT02975687
unknownphase_1

T-cells Expressing Anti-CD19 CAR in Pediatric and Young Adults With B-cell Malignancies

NCT02772198

Clinical Trials (4)

Showing 4 of 4 trials
NCT03029338Phase 1

CD19 CAR T Cells in Patients With Relapsed or Refractory CD19 Positive B-cell Lymphoma

Completed
NCT07277504Early Phase 1

Autologous Bedside CD19 CAR T-cell Therapy for B-ALL

Not Yet Recruiting
NCT02975687Phase 1

CD19 CAR T Cells in Patients With Resistant or Refractory CD19+ Acute Lymphoblastic Leukemia

Completed
NCT02772198Phase 1

T-cells Expressing Anti-CD19 CAR in Pediatric and Young Adults With B-cell Malignancies

Unknown

All 4 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
4